報價延遲最少15分鐘:2025/07/16 09:14 EDT
盤前時段
|
||||
|
464.34 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
--
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.82/19.69
|
|
企業價值
120.86B
|
| 資產負債 |
|
每股賬面淨值
64.24
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
11.02B
|
|
每股收益
37.59
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/07/16 09:14 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. |
